Nöroendokrin tümörlerinin iyot 131 MIBG sintigrafisi ile değerlendirilmesi
Amaç: İyot-131-metaiyodobenzilguanetidin (I-131 MIBG) sintigrafisinin nöroendokrin tümörlü hastaların tanı, evrelemede ve uzun takip süreleri boyunca gelişebilecek nükslerinin tespitindeki rolünü değerlendirmeyi amaçladık. Gereç ve Yöntemler: Kliniğimize Ocak 2006- Mayıs 2008 tarihleri arasında I-131 MIBG ile sintigrafik görüntüleme istemiyle başvuran toplam 64 hasta çalışmaya dahil edildi. I-131 MIBG sintigrafisi ile patolojik tutulum saptanan hastalar biyopsi veya cerrahi patoloji sonuçlarıyla karşılaştırıldı. Sintigrafide patolojik tutulum sahası saptanmayan hastalar ise 6 ay süresince takip edildi. Bulgular: I-131 MIBG ile 64 hastanın 17’sinde patolojik tutulum saptandı. 15 hasta histopatolojik olarak doğrulandı. 1 hasta diğer yöntemlerle korele edildi, patolojik doğrulamaya gerek duyulmaksızın tedaviye alındı. Tedavi sonrası patolojik tutulumun kaybolduğu izlendi. 1 hastada histopatolojik tanı ile I-131 MIBG tutulumunun yanlış pozitif olduğu saptandı. 64 hastanın 47 sinde I-131 MIBG dağılımı fizyolojik sınırlarda saptandı. Çekim sırasında veya 6 ay süreyle yapılan takiplerde; 7 hastada I-131 MIBG sintigrafisi negatif olduğu halde, nöral krest tümörü ile uyumlu histopatoloji saptandı. 11 hastanın cerrahi ya da biopsi ile histopatoloji sonucuna ulaşıldı ve I-131 MIBG negatifliği doğrulandı. 29 hastanın 6 aylık takibinde bulgularda değişiklik izlenmedi. Sonuç: Feokromasitoma, nöroblastoma ve benzer nöroendokrin kökenli tümörlerin tanı ve takipleri süresince I-131 MIBG ile yapılan sintigrafik görüntülemenin kullanımı gerek yetişkin gerekse pediatrik yaş gruplarında konvansiyonel radyolojik yöntemlerle elde edilemeyen önemli ve vazgeçilmez bilgiler sunmaktadır. Anahtar Kelimeler: Nöroendokrin tümörler; nöroblastoma; feokromositoma; paragangliyom; tiroid tümörleri; radyonuklit görüntüleme; iyot izotopları
Evaluation of neuroendocrine tumors with I-131 MIBG scintigraphy
We aimed to evaluate the role of Iodine -131 metaiodobenzylguanidine (I-131 MIBG) scintigraphy in the diagnosis and staging of neuroendocrine tumors and detecting the recurrences that may have developed over the long follow-up periods. Material and Methods: Total of 64 patients referred to our clinic between January 2006 and May 2008 with a request for an I-131 MIBG scintigraphic imaging were included in the study. The patients who had pathological uptake on I-131 MIBG scintigraphy were confirmed with biopsy or surgical pathology outcomes. The patients with no I-131 MIBG uptake were followed-up for 6 months. Results: Pathological involvement was defined in 17 of 64 patients. Fifteen patients were histopathologically confirmed. One patient was correlated with the other methods and treated without a need of pathological confirmation. Disappearance of pathological involvement was observed after the treatment. False positivity of I-131 MIBG involvement was defined in one patient by histopathological diagnosis. I-131 MIBG distribution was found within normal physiologic limits in 47 of 64 patients. By scintigraphy or at the follow-up of 6 month period, histopathology in compliance with neural crest tumor was identified in 7 patients despite I-131 MIBG scintigraphy was negative. Surgical or histopathological outcomes with biopsy were reached for 11 patients and I-131 MIBG negativity was confirmed. There was not any change detected in the findings of 29 patients for the 6 month period. Conclusion: During the diagnosis and follow-up of pheochromocytoma, neuroblastoma, and similar neuroendocrine originated tumors, the use of I-131 -MIBG scintigraphy in both adult and pediatric age groups offers important and indispensable information that can not be obtained by other conventional radiological methods.
___
- 1. Pashankar FD, Dorisio S, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med 2005; 46 Suppl 1:55S-61S.
- 2. Englaro EE, Gelfand MJ, Harris RE, Smith HS. I-131 MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology 1992: 182 (2): 515-20.
- 3. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine- 123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-
- 4. Roelants V, Goulios C, Jamar F. Iodine-131- MIBG scintigraphy in adults: Interpretation revisited? J Nucl Med 1998; 39(6):1007-12.
- 5. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39(4):679-88.
- 6. Bravo EL. Adrenal medullary function. Diagnostic Endocrinology. In: Moore TB, Eastman RC, eds. Mosby Inc; 1996. p. 299-309 .
- 7. Lebtahi N, Gudinchet F, Nenadov-Beck M, Beck D, Bischof Delaloye A. Evaluating bone marrow metastasis of neuroblastoma with Iodine- 123-MIBG scintigraphy and MRI. J Nucl Med 1997; 38(9):1389-92
- 8. Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG, Lee JM. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics 2003; 23(1):29-43.
- 9. Shapiro B, Copp JE, Sisson JE, Eyre PL, Wallis J.Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experienced in 400 cases. J Nucl Med 1985:26(6): 576-85.
- 10. Limouris GS, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L. Comparison of Indium- 111-pentetreotide, Tc-99m (V) DMSA and I-123 MIBG scintiimaging in neural crest tumors. Anticancer Res 1997: 17(3B):1589-92.
- 11. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine- 131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34(2):173-9.
- 12. Maurea S, Lastoria S, Caraco C, Indolfi P, Casale F, di Tullio MT, et al. Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis. J Nucl Med 1994; 35(9):1429-35.
- 13. Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In- 111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001:26(8):683-8.
- 14. Turkmen C, Adalet I, Sönmezoğlu K. Tiroid kanserlerinde pozitron emisyon tomografisi, Endokrinolojide Diyalog 2004;1(1): 3.
- 15. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. From the archives of the AFIP. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002; 22(4):911-34.
- 16. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer 2005;4(1):61-8.
- 17. Demir H, Ak İ, Aydın A, Bekiş R, Bozkurt F, Burak Z, et al. 123 I / 131 I Metaiyodobenzilguanidin (MIBG) sintigrafisi uygulama kılavuzu Turk J Nucl Med 2003; 12:181-5.
- 18. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, et al. Favorable prognosis for patients ages 12-18 months with stage 4 MYCN nonamplified neuroblastoma: a children’s cancer study group study. J Clin Oncol 2005;23 (27):6474-80.
- 19. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine– 131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992: 33(10):1735-40.